Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $19.30.

A number of equities research analysts have recently commented on YMAB shares. Bank of America lowered their target price on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Truist Financial decreased their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Brookline Capital Management started coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its position in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Barclays PLC grew its holdings in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after buying an additional 56,244 shares in the last quarter. Geode Capital Management LLC grew its holdings in Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after buying an additional 47,846 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at about $133,000. Finally, Caligan Partners LP lifted its holdings in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after buying an additional 613,175 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

NASDAQ:YMAB opened at $5.16 on Friday. Y-mAbs Therapeutics has a 52 week low of $4.25 and a 52 week high of $18.10. The firm has a 50-day moving average price of $6.34 and a two-hundred day moving average price of $10.54. The firm has a market cap of $231.11 million, a price-to-earnings ratio of -9.56 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million for the quarter, compared to analysts’ expectations of $26.70 million. During the same period in the previous year, the business posted ($0.02) earnings per share. As a group, sell-side analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.